Literature DB >> 18273039

Effect of metabolic syndrome or type II diabetes mellitus on the occurrence of recurrent vascular events in hypertensive patients.

A L M Vlek1, Y van der Graaf, W Spiering, F L J Visseren.   

Abstract

Patients with hypertension and manifest vascular disease are at high risk for recurrent cardiovascular diseases. It is unknown if the metabolic syndrome further increases the risk in these patients. This study aims to quantify the effect of metabolic syndrome and type II diabetes on cardiovascular events in hypertensive patients with vascular disease. A total of 2,196 hypertensive patients with vascular disease (cerebrovascular disease (34%), coronary heart disease (50%), peripheral arterial disease (28%), abdominal aortic aneurysm (13%)) from the Second Manifestations of Arterial Disease study were followed for up to 10 years (mean 3.9 years) for death, stroke and myocardial infarction. Age and sex adjusted hazard ratios (HR) were calculated for hypertensive patients with metabolic syndrome but without diabetes (n=775) and for hypertensive patients with type II diabetes (n=381), compared to merely hypertensive patients (n=1,040). Forty-nine percent had metabolic syndrome (NCEP ATPIII definition) and 17% had type II diabetes. Metabolic syndrome predicted vascular death (HR 1.41, 95% confidence interval (CI) 1.01-1.98), stroke (HR 1.36, 95% CI 0.85-2.16) and myocardial infarction (HR 1.40, 95% CI 0.97-2.01). Type II diabetes accounted for even higher risks of vascular end points (HR 1.41-1.64). The effect of metabolic syndrome on future events could not be explained by the presence of type II diabetes. Even in high-risk patients with hypertension and vascular disease, presence of metabolic syndrome or type II diabetes identifies patients at high risk for future cardiovascular events. Identifying metabolic syndrome patients may direct therapy focusing on treatment of insulin resistance by reducing weight and increasing physical activity.

Entities:  

Mesh:

Year:  2008        PMID: 18273039     DOI: 10.1038/jhh.2008.5

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  7 in total

Review 1.  Metabolic syndrome in hypertensive patients: An unholy alliance.

Authors:  Giuseppe Mulè; Ilenia Calcaterra; Emilio Nardi; Giovanni Cerasola; Santina Cottone
Journal:  World J Cardiol       Date:  2014-09-26

Review 2.  [Treatment of hypertension in diabetic patients].

Authors:  Jörg Slany
Journal:  Wien Med Wochenschr       Date:  2010-01

3.  Effects of manidipine and its combination with an ACE inhibitor on insulin sensitivity and metabolic, inflammatory and prothrombotic markers in hypertensive patients with metabolic syndrome: the MARCADOR study.

Authors:  Francisco J Martinez-Martin; Alicia Macias-Batista; Cristina Comi-Diaz; Herminia Rodriguez-Rosas; Paula Soriano-Perera; Pablo Pedrianes-Martin
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

4.  Liver fat percent is associated with metabolic risk factors and the metabolic syndrome in a high-risk vascular cohort.

Authors:  Michel R Hoenig; Gary Cowin; Raymond Buckley; Christine McHenery; Alan Coulthard
Journal:  Nutr Metab (Lond)       Date:  2010-06-16       Impact factor: 4.169

5.  MRI sagittal abdominal diameter is a stronger predictor of metabolic syndrome than visceral fat area or waist circumference in a high-risk vascular cohort.

Authors:  Michel R Hoenig
Journal:  Vasc Health Risk Manag       Date:  2010-08-09

Review 6.  Update on the metabolic syndrome: hypertension.

Authors:  Kristi Reynolds; Rachel P Wildman
Journal:  Curr Hypertens Rep       Date:  2009-04       Impact factor: 5.369

7.  Low density lipoprotein cholesterol is inversely correlated with abdominal visceral fat area: a magnetic resonance imaging study.

Authors:  Michel R Hoenig; Gary Cowin; Raymond Buckley; Christine McHenery; Allan Coulthard
Journal:  Lipids Health Dis       Date:  2011-01-19       Impact factor: 3.876

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.